Replies to post #154228 on Biotech Values

[gfp927z]

Biomaven, Any thoughts on Ariad in light of recent developments?

Thanks.

[DewDiligence]

Six-month exclusivity for first-filer status on US generics is a less consequential part of Teva’s business model than it used to be. The acquisitions of Cephalon and Ratiopharm have turned Teva into a much different company.